Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Allergy may confer better survival on patients with gliomas.

Lehrer S, Rheinstein PH, Rosenzweig KE.

Clin Neurol Neurosurg. 2019 Feb;177:63-67. doi: 10.1016/j.clineuro.2018.12.021. Epub 2018 Dec 31.

2.

Loss of MycBP may be associated with the improved survival in 1P co-deletion of lower grade glioma patients.

Lehrer S, Rheinstein PH, Rosenzweig KE.

Clin Neurol Neurosurg. 2018 Sep;172:112-115. doi: 10.1016/j.clineuro.2018.07.003. Epub 2018 Jul 5.

PMID:
29986195
3.

Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.

Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T, Motomura K, Ohka F, Shiina S, Yamamoto T, Nagata Y, Yoshizato T, Mizoguchi M, Abe T, Momii Y, Muragaki Y, Watanabe R, Ito I, Sanada M, Yajima H, Morita N, Takeuchi I, Miyano S, Wakabayashi T, Ogawa S, Natsume A.

Neuro Oncol. 2018 Jan 10;20(1):66-77. doi: 10.1093/neuonc/nox132.

4.

DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.

Paul Y, Mondal B, Patil V, Somasundaram K.

Clin Epigenetics. 2017 Apr 4;9:32. doi: 10.1186/s13148-017-0331-9. eCollection 2017.

5.

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.

Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O'Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhim R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Guin R, Hadjipanayis A, Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD, Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Protopopov A, Ren X, Roach J, Sabedot TS, Schein J, Schumacher SE, Seidman JG, Seth S, Shen H, Simons JV, Sipahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Triche T Jr, Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T, Wu J, Xi L, Xu AW, Yang L, Zack TI, Zhang J, Aksoy BA, Arachchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J, Gehlenborg N, Haussler D, Heiman DI, Iype L, Jacobsen A, Ju Z, Katzman S, Kim H, Knijnenburg T, Kreisberg RB, Lawrence MS, Lee W, Leinonen K, Lin P, Ling S, Liu W, Liu Y, Liu Y, Lu Y, Mills G, Ng S, Noble MS, Paull E, Rao A, Reynolds S, Saksena G, Sanborn Z, Sander C, Schultz N, Senbabaoglu Y, Shen R, Shmulevich I, Sinha R, Stuart J, Sumer SO, Sun Y, Tasman N, Taylor BS, Voet D, Weinhold N, Weinstein JN, Yang D, Yoshihara K, Zheng S, Zhang W, Zou L, Abel T, Sadeghi S, Cohen ML, Eschbacher J, Hattab EM, Raghunathan A, Schniederjan MJ, Aziz D, Barnett G, Barrett W, Bigner DD, Boice L, Brewer C, Calatozzolo C, Campos B, Carlotti CG Jr, Chan TA, Cuppini L, Curley E, Cuzzubbo S, Devine K, DiMeco F, Duell R, Elder JB, Fehrenbach A, Finocchiaro G, Friedman W, Fulop J, Gardner J, Hermes B, Herold-Mende C, Jungk C, Kendler A, Lehman NL, Lipp E, Liu O, Mandt R, McGraw M, Mclendon R, McPherson C, Neder L, Nguyen P, Noss A, Nunziata R, Ostrom QT, Palmer C, Perin A, Pollo B, Potapov A, Potapova O, Rathmell WK, Rotin D, Scarpace L, Schilero C, Senecal K, Shimmel K, Shurkhay V, Sifri S, Singh R, Sloan AE, Smolenski K, Staugaitis SM, Steele R, Thorne L, Tirapelli DP, Unterberg A, Vallurupalli M, Wang Y, Warnick R, Williams F, Wolinsky Y, Bell S, Rosenberg M, Stewart C, Huang F, Grimsby JL, Radenbaugh AJ, Zhang J.

N Engl J Med. 2015 Jun 25;372(26):2481-98. doi: 10.1056/NEJMoa1402121. Epub 2015 Jun 10.

6.

SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.

Zhang YA, Zhou Y, Luo X, Song K, Ma X, Sathe A, Girard L, Xiao G, Gazdar AF.

EBioMedicine. 2016 Nov;13:80-89. doi: 10.1016/j.ebiom.2016.10.040. Epub 2016 Oct 28.

7.

PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.

Draaisma K, Wijnenga MM, Weenink B, Gao Y, Smid M, Robe P, van den Bent MJ, French PJ.

Acta Neuropathol Commun. 2015 Dec 23;3:88. doi: 10.1186/s40478-015-0265-4.

8.

IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.

Otani R, Uzuka T, Higuchi F, Matsuda H, Nomura M, Tanaka S, Mukasa A, Ichimura K, Kim P, Ueki K.

Cancer Sci. 2018 Jul;109(7):2327-2335. doi: 10.1111/cas.13635. Epub 2018 Jun 15.

9.

Loss of heterozygosity 1p/19q and survival in glioma: a meta-analysis.

Zhao J, Ma W, Zhao H.

Neuro Oncol. 2014 Jan;16(1):103-12. doi: 10.1093/neuonc/not145. Epub 2013 Dec 4.

10.

A network model of a cooperative genetic landscape in brain tumors.

Bredel M, Scholtens DM, Harsh GR, Bredel C, Chandler JP, Renfrow JJ, Yadav AK, Vogel H, Scheck AC, Tibshirani R, Sikic BI.

JAMA. 2009 Jul 15;302(3):261-75. doi: 10.1001/jama.2009.997.

11.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

12.

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.

Leeper HE, Caron AA, Decker PA, Jenkins RB, Lachance DH, Giannini C.

Oncotarget. 2015 Oct 6;6(30):30295-305. doi: 10.18632/oncotarget.4497.

13.

ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.

Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DT, Hovestadt V, Mittelbronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, Weller M, Wick W, Pfister SM, von Deimling A.

Acta Neuropathol. 2015 Jan;129(1):133-46. doi: 10.1007/s00401-014-1370-3. Epub 2014 Nov 27.

14.

Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.

Karsy M, Guan J, Huang LE.

J Neurosurg. 2018 Mar 1:1-11. doi: 10.3171/2017.9.JNS172036. [Epub ahead of print]

PMID:
29547090
15.

Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas.

Iwamoto FM, Nicolardi L, Demopoulos A, Barbashina V, Salazar P, Rosenblum M, Hormigo A.

J Neurooncol. 2008 Jul;88(3):293-8. doi: 10.1007/s11060-008-9563-z. Epub 2008 Mar 15.

PMID:
18345516
16.

Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma.

Tanaka K, Sasayama T, Mizukawa K, Takata K, Sulaiman NS, Nishihara M, Kohta M, Sasaki R, Hirose T, Itoh T, Kohmura E.

Clin Neurol Neurosurg. 2015 Nov;138:37-44. doi: 10.1016/j.clineuro.2015.07.019. Epub 2015 Jul 31.

PMID:
26276726
17.

Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies.

Di Stefano AL, Enciso-Mora V, Marie Y, Desestret V, Labussière M, Boisselier B, Mokhtari K, Idbaih A, Hoang-Xuan K, Delattre JY, Houlston RS, Sanson M.

Neuro Oncol. 2013 May;15(5):542-7. doi: 10.1093/neuonc/nos284. Epub 2012 Nov 16.

18.

Sexual dimorphism in glioma glycolysis underlies sex differences in survival.

Ippolito JE, Yim AK, Luo J, Chinnaiyan P, Rubin JB.

JCI Insight. 2017 Aug 3;2(15). pii: 92142. doi: 10.1172/jci.insight.92142. eCollection 2017 Aug 3.

19.

A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.

Patil V, Mahalingam K.

Gene. 2018 Dec 30;679:57-64. doi: 10.1016/j.gene.2018.08.001. Epub 2018 Aug 2.

PMID:
30077762

Supplemental Content

Support Center